GlassScriptPhysician profile
Emily A Potter
NPI 1699381418
$475.71
in general payments reported to CMS, 2019-2025
24 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.70 · 2023: $73.79 · 2024: $132 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $40.11 | 2024-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $35.34 | 2023-2024 | |
| Ardelyx, INC. | $35.16 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $31.07 | 2023-2025 | |
| Boston Scientific Corporation | $25.58 | 2025 | Watchman Access System |
| Medtronic, INC. | $24.40 | 2025 | Inceptiv |
| Phathom Pharmaceuticals, INC. | $20.06 | 2025 | Voquezna |
| Dexcom, INC. | $19.34 | 2025 | Dexcom G6 Transmitter |
| Calliditas Therapeutics US INC. | $18.81 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $17.70 | 2024 | |
| Exact Sciences Corporation | $16.28 | 2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $16.26 | 2025 | Uptravi, Opsumit |
| Amgen INC. | $15.94 | 2025 | Repatha, Otezla |
| Electromed, INC. | $15.76 | 2024 | Smartvest |
| Apellis Pharmaceuticals, INC. | $15.57 | 2025 | Empaveli |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $15.20 | 2024 | Injectafer |
| Collegium Pharmaceutical, INC. | $15.01 | 2025 | Belbuca |
| Jazz Pharmaceuticals INC. | $14.70 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.61 | 2024 | Jynarque |
| Glaxosmithkline, LLC. | $14.56 | 2024 | Shingrix |
| Surgenex LLC | $14.42 | 2025 | Surgraft, Ardeograft, Surmatrix |
| Horizon Therapeutics Plc | $13.38 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $13.27 | 2023 | Verquvo |
| Genzyme Corporation | $13.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.